Is Ajanta Pharma (AJANTPHARM) overvalued or fairly valued?

MarketChacha shows Ajanta Pharma's valuation in context — a forward P/E of about 30.4, a price-to-book of about 9.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Ajanta Pharma's revenue?

Ajanta Pharma reported revenue of ₹5,453 Cr for FY2026, with net profit of ₹1,056 Cr, per official filings.

What is the share price of Ajanta Pharma (AJANTPHARM)?

Ajanta Pharma last traded at ₹3,458.90 (-0.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Ajanta Pharma

AJANTPHARM · NSE · Pharma · India

₹3,458.90-0.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerAJANTPHARM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersMumbai, India

Market cap₹43,214 Cr

P/B9.5

Volume97.04K

Websitewww.ajantapharma.com

Filings tracked0

About Ajanta Pharma

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters54.5%
Institutions21.8%
Public & other23.7%

93 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend15.7% → 19.4%

Margin has expanded by about 3.7 points — the business is getting more profitable.

Growth qualityrev 13% · PAT 22%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,528 Cr

Next fiscal year

Rev ₹7,034 Cr · EPS 113.84

Est. earnings growth +15.9%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹2,329.9052-wk range₹3,598.80

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹43,214 Cr

Day change

-0.3%

Fwd P/E

30.4

P/B

9.5

Div yield

1.57%

Beta

0.18

Revenue (FY2026)

₹5,453 Cr

Net margin

19.4%

Revenue CAGR (3y)

+13.4%

Profit CAGR (3y)

+21.6%

Net profit (FY2026)

₹1,056 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about AJANTPHARM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹5,453 Cr	₹1,056 Cr	19.4%
FY2025	₹4,648 Cr	₹920 Cr	19.8%
FY2024	₹4,209 Cr	₹816 Cr	19.4%
FY2023	₹3,743 Cr	₹588 Cr	15.7%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹1,422 Cr	₹267 Cr	18.8%
2025Q4	₹1,375 Cr	₹274 Cr	19.9%
2025Q3	₹1,354 Cr	₹260 Cr	19.2%
2025Q2	₹1,303 Cr	₹255 Cr	19.6%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.